Research and Development
Research and Development
CellGenix develops novel and effective therapeutics with the aid of the most advanced technologies from the fields of cell biology, molecular biology and immunology. The research and development activities of CellGenix focus on diseases with a large and growing need for medicinal therapies: cancer and degenerative/ traumatic bone and cartilage disorders. Our goal is to achieve a more rapid and efficient transfer of new technologies from the area of medical research to practical clinical applications. CellGenix has a great deal of expertise in this field, a fact which is evidenced by the products that have already been commercialized.
Mesenchymal Stem Cells |
Mesenchymal Stem Cells: |
Chondrocytes culture |
Molecular Therapeutics
Idiotype vaccination process |
For patients with Non-Hodgkin´s B-cell lymphomas CellGenix is developing a patient-specific recombinant vaccine. This idiotype vaccine (IdioVax®) is currently in a Phase II clinical trial, which is performed in cooperation with the University Medical Center and the Center for Clinical Research in Freiburg. The product has already obtained EMEA´s Orphan Drug status and a Phase III trial is scheduled to begin early next year. |
Cellular Therapeutics
Umbillical cord slice culture |
Currently there are different research projects going on, parts of them in widespread collaborations of various labs, like the development of serum-free and animal derived component free media for the expansion of bone marrow derived mesenchymal stem cells, the characterization of adherent cord blood stem cells for cell therapeutic applications, the colonisation of different scaffold materials with stem cells or the development of a cell therapeutic treatment for muscular dystrophy. |
Ex Vivo Therapeutics
Dendritic cell & 3D Cytokine model |
R&D focus is the development of advanced cell processing technologies and their necessary reagents and tools: closed kit systems, serum-free media for various cell types and cytokines for the expansion and differentiation of cells used for clinical cell therapy applications. A further important developmental goal for all our product candidates is to reach GMP-quality to provide a maximum of regulatory compliance. |
